Skip to main content
SpringerLink
Log in

Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer

  • Protocol
  • First Online:
Urothelial Carcinoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1655))

Abstract

The PI3K/AKT/mTOR signaling pathway shows frequent molecular alterations and increased activity in cancer. Given its role in the regulation of cell growth, survival and metastasis, molecules within this pathway are promising targets for pharmacologic intervention. Metastatic bladder cancer (BLCA) continues to have few treatment options. Although various molecular alterations in PI3K/AKT/mTOR signaling have been described in BLCA, clinical trials with small molecule inhibitors have not met their endpoints. In this article, we summarize results from preclinical studies and clinical trials that examined PI3K pathway inhibitors in BLCA focusing on technical challenges that might result in contradictory findings in preclinical studies. Based on published data from our group, we also address challenges that need to be overcome to optimize PI3K inhibition in BLCA and enable its successful translation into the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606–619. doi:10.1038/nrg1879

    Article  CAS  PubMed  Google Scholar 

  2. Franke TF (2008) PI3K/Akt: getting it right matters. Oncogene 27(50):6473–6488. doi:10.1038/onc.2008.313

    Article  CAS  PubMed  Google Scholar 

  3. Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589–3594. doi:10.1242/jcs.051011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25(48):6416–6422. doi:10.1038/sj.onc.1209888

    Article  CAS  PubMed  Google Scholar 

  5. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322. doi:10.1038/nature12965

    Article  Google Scholar 

  6. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31(25):3133–3140. doi:10.1200/JCO.2012.46.5740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15(19):6008–6017. doi:10.1158/1078–0432.CCR-09-0898. [pii]

    Article  CAS  PubMed  Google Scholar 

  8. Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Herault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y (2014) PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 134(8):1776–1784. doi:10.1002/ijc.28518

    Article  CAS  PubMed  Google Scholar 

  9. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F (1997) Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14(25):3059–3066. doi:10.1038/sj.onc.1201154

    Article  CAS  PubMed  Google Scholar 

  10. Aveyard JS, Skilleter A, Habuchi T, Knowles MA (1999) Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80(5–6):904–908. doi:10.1038/sj.bjc.6690439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, Tsuchiya N, Enomoto K, Mak TW, Nakano T, Habuchi T, Suzuki A (2006) Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 66(17):8389–8396. doi:10.1158/0008-5472.CAN-05-4627

    Article  CAS  PubMed  Google Scholar 

  12. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D (2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63(22):7652–7656

    CAS  PubMed  Google Scholar 

  13. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA (2010) AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29(1):150–155. doi:10.1038/onc.2009.315

    Article  CAS  PubMed  Google Scholar 

  14. Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskimae E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475. doi:10.1016/j.eururo.2016.06.020

    Article  CAS  PubMed  Google Scholar 

  15. Ratner M (2016) Genentech's PD-L1 agent approved for bladder cancer. Nat Biotechnol 34(8):789–790. doi:10.1038/nbt0816-789

    Article  CAS  PubMed  Google Scholar 

  16. Dienstmann R, Rodon J, Serra V, Tabernero J (2014) Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13(5):1021–1031. doi:10.1158/1535-7163.MCT-13-0639

    Article  CAS  PubMed  Google Scholar 

  17. Shimobayashi M, Hall MN (2014) Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15(3):155–162. doi:10.1038/nrm3757

    Article  CAS  PubMed  Google Scholar 

  18. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140–156. doi:10.1038/nrd4204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M (2011) S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 6(11):e27509. doi:10.1371/journal.pone.0027509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17(9):2863–2873. doi:10.1158/1078-0432.CCR-09-3202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lin JF, Lin YC, Yang SC, Tsai TF, Chen HE, Chou KY, Hwang TI (2016) Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells. Drug Des Devel Ther 10:1501–1513. doi:10.2147/DDDT.S95900

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kyou Kwon J, Kim SJ, Hoon Kim J, Mee Lee K, Ho Chang I (2014) Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer. Urol Oncol 32(1):51 e27-35. doi:10.1016/j.urolonc.2013.08.005

    PubMed  Google Scholar 

  23. Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL, Kwiatkowski DJ (2013) TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 230(1):17–27. doi:10.1002/path.4176

    Article  CAS  PubMed  Google Scholar 

  24. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O (2013) PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer 109(6):1586–1592. doi:10.1038/bjc.2013.505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284(12):8023–8032. doi:10.1074/jbc.M900301200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38. doi:10.1371/journal.pbio.1000038

    Article  PubMed  Google Scholar 

  27. Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22(2):169–176. doi:10.1016/j.ceb.2009.10.007

    Article  CAS  PubMed  Google Scholar 

  28. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104):221. doi:10.1126/science.1226344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23(10):2663–2670. doi:10.1093/annonc/mds057

    Article  CAS  PubMed  Google Scholar 

  30. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE (2014) Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 4(5):546–553. doi:10.1158/2159-8290.CD-13-0353

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R (2014) Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 111(11):2103–2113. doi:10.1038/bjc.2014.534

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ (2012) Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 13(13):1325–1338. doi:10.4161/cbt.21793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ross RL, McPherson HR, Kettlewell L, Shnyder SD, Hurst CD, Alder O, Knowles MA (2016) PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer 16:553. doi:10.1186/s12885-016-2570-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gopa Iyer CMT, Garcia-Grossman IR, Scott SN, Boyd ME, McCoy AS, Berger MF, Al-Ahmadie H, Solit DB, Rosenberg JE, Bajorin DF (2015) Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients. J Clin Oncol 33(suppl 7):abstr 324

    Article  Google Scholar 

  35. Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J (2014) NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 45(3):1027–1035. doi:10.3892/ijo.2014.2505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL (2013) Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Toxicol Lett 220(3):267–276. doi:10.1016/j.toxlet.2013.04.021

    Article  CAS  PubMed  Google Scholar 

  37. Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP (2016) Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int 118(3):408–415. doi:10.1111/bju.13415

    Article  CAS  PubMed  Google Scholar 

  38. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016) First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res 22(8):1932–1939. doi:10.1158/1078-0432.CCR-15-1665

    Article  CAS  PubMed  Google Scholar 

  39. Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3):143–153. doi:10.1038/nrclinonc.2013.10

    Article  CAS  PubMed  Google Scholar 

  40. Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W (2013) Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment. PLoS One 8(6):e65257. doi:10.1371/journal.pone.0065257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25–41. doi:10.1038/nrc3817

    Article  CAS  PubMed  Google Scholar 

  42. Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D (2017) Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 36:35–46. doi:10.1038/onc.2016.172

    Article  CAS  PubMed  Google Scholar 

  43. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607. doi:10.1038/nature11003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ (2015) COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(Database issue):D805–D811. doi:10.1093/nar/gku1075

    Article  CAS  PubMed  Google Scholar 

  45. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L (2004) Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD)

    Google Scholar 

  46. Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, Bourgon R (2016) Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533(7603):333–337. doi:10.1038/nature17987

    Article  CAS  PubMed  Google Scholar 

  47. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J (2013) Inconsistency in large pharmacogenomic studies. Nature 504(7480):389–393. doi:10.1038/nature12831

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Boettcher M, McManus MT (2015) Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 58(4):575–585. doi:10.1016/j.molcel.2015.04.028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116. doi:10.1038/nprot.2006.179

    Article  CAS  PubMed  Google Scholar 

  50. Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stockle M, Bogemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P (2015) Second-line treatment of advanced Urothelial cancer with paclitaxel and Everolimus in a German phase II trial (AUO trial AB 35/09). Oncology 89(2):70–78. doi:10.1159/000376551

    Article  CAS  PubMed  Google Scholar 

  51. Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF (2013) Phase II study of everolimus in metastatic urothelial cancer. BJU Int 112(4):462–470. doi:10.1111/j.1464-410X.2012.11720.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C, Otto T (2012) A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 29(4):2870–2876. doi:10.1007/s12032-012-0216-x

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany

    Anuja Sathe & Roman Nawroth

Authors
  1. Anuja Sathe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roman Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Nawroth .

Editor information

Editors and Affiliations

  1. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Wolfgang A Schulz

  2. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Michèle J. Hoffmann

  3. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Günter Niegisch

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Sathe, A., Nawroth, R. (2018). Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. In: Schulz, W., Hoffmann, M., Niegisch, G. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 1655. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7234-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7234-0_23

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7233-3

  • Online ISBN: 978-1-4939-7234-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation